You’ve likely been infected. Not with the latest flu strain, or even COVID-19, but with a virus that quietly resides within the vast majority of us – up to 90 percent, according to recent estimates. The human polyomavirus 2, more commonly known as the JC virus, has been a silent passenger in our bodies for years, even decades, without causing harm. But emerging research suggests a potential new trigger for this virus to awaken, and when it does, the consequences can be devastating, leading to a rare but often fatal brain disease. Understanding the latest findings about the JC virus and progressive multifocal leukoencephalopathy (PML) is crucial, even if the risk to any individual remains low.
The JC virus was first identified in 1971, named after the initials of the patient – “John Cunningham” – from whom it was initially isolated. It spreads through common routes, primarily via the fecal-oral route, meaning it’s present in urine and stool. Infection typically occurs early in life, often without any noticeable symptoms. Blood testing surveys indicate that between 50 and 90 percent of adults have been exposed to the virus at some point, according to research published in the journal PLoS Pathogens. After the initial infection, the virus enters a dormant state, establishing a persistent, lifelong infection known as the “archetype JC virus,” as described in research from Viruses.
A Silent Threat: Understanding PML
For the vast majority of people, the JC virus remains dormant, posing no threat. Yet, in a small percentage of individuals, the virus reactivates, transforming into a form capable of causing progressive multifocal leukoencephalopathy, or PML. This isn’t a simple reactivation; the virus undergoes genetic changes, essentially morphing into a brain-attacking variant. PML specifically targets oligodendrocytes – the cells responsible for producing myelin, the protective sheath around nerve fibers. As the virus destroys these cells, it leads to demyelination, disrupting nerve signal transmission and ultimately causing neurological dysfunction.
The symptoms of PML are often insidious and can mimic other neurological conditions, making diagnosis challenging. They can include speech difficulties, vision problems, motor weakness, and seizures. Diagnosis typically relies on identifying characteristic lesions in the brain through imaging techniques like MRI, coupled with detecting JC virus DNA in cerebrospinal fluid. The National Institute of Neurological Disorders and Stroke provides detailed information on PML, including symptoms and diagnostic procedures.
From Rare Disease to AIDS-Defining Illness and Back Again
PML was first recognized in 1958 in a patient with cancer, but remained exceedingly rare for decades. The disease’s prevalence dramatically increased in the 1980s with the emergence of the HIV/AIDS epidemic. PML became an AIDS-defining illness, affecting 2 to 5 percent of individuals infected with HIV, particularly in the early stages of the epidemic. At that time, a PML diagnosis was almost invariably fatal.
The introduction of highly active antiretroviral therapy (HAART) in 1996 marked a turning point. HAART effectively suppresses the HIV virus, bolstering the immune system and significantly reducing the incidence of PML among people living with HIV. While PML is no longer a guaranteed death sentence thanks to HAART, survivors often experience lasting neurological damage. However, in recent years, a new wave of PML cases has emerged, linked not to HIV, but to certain immunosuppressive therapies used to treat autoimmune diseases like multiple sclerosis, Crohn’s disease, and psoriasis.
New Activation Pathways and Emerging Concerns
The recent research, published in the Annals of Internal Medicine, highlights a potential new pathway for JC virus activation. Researchers are investigating whether certain biological therapies, specifically those targeting B-cells – a type of immune cell – may inadvertently create an environment conducive to viral reactivation. The study suggests that up to 10 percent of adults worldwide receiving these therapies could be at risk. This finding is prompting a reevaluation of the risk-benefit profiles of these medications and a closer monitoring of patients for signs of PML.
The exact mechanisms by which these therapies trigger reactivation are still under investigation. It’s believed that suppressing B-cell activity may weaken the immune system’s ability to keep the JC virus in check, allowing it to reactivate and cause PML. Further research is needed to identify individuals who are most susceptible and to develop strategies for preventing PML in those receiving immunosuppressive treatments.
While the risk of developing PML remains low for the general population, the increasing use of immunosuppressive therapies means more people may be vulnerable. Awareness of the JC virus and PML is crucial for both patients and healthcare providers. Early diagnosis and prompt treatment – typically involving reducing or stopping the triggering immunosuppressive therapy – are essential for improving outcomes.
Researchers continue to investigate potential antiviral therapies specifically targeting the JC virus, but currently, We find no FDA-approved drugs for treating PML directly. Management focuses on restoring immune function and controlling the symptoms of the disease. The National Organization for Rare Disorders (NORD) offers comprehensive information and support resources for individuals and families affected by PML.
The next key step in understanding and combating PML will be the results of ongoing clinical trials evaluating the effectiveness of various treatment strategies. Researchers are also working to develop more sensitive and accurate diagnostic tools for early detection of JC virus reactivation. For those currently undergoing immunosuppressive therapy, regular monitoring and open communication with your healthcare provider are paramount.
This is a developing story, and continued research is vital. Share your thoughts and experiences in the comments below, and please share this article to facilitate raise awareness about the silent threat of the JC virus.
Keep reading
